Corindus Vascular Robotics Inc (NYSEMKT:CVRS) was downgraded by stock analysts at BidaskClub from a “buy” rating to a “hold” rating in a research note issued to investors on Monday, July 24th.

Other research analysts have also issued reports about the stock. B. Riley reaffirmed a “buy” rating and issued a $3.00 price target on shares of Corindus Vascular Robotics in a report on Monday, May 15th. ValuEngine upgraded shares of Corindus Vascular Robotics from a “sell” rating to a “hold” rating in a research report on Thursday, June 22nd. Finally, Zacks Investment Research downgraded shares of Corindus Vascular Robotics from a “hold” rating to a “sell” rating in a research report on Tuesday, May 16th. Two analysts have rated the stock with a sell rating and three have issued a buy rating to the company’s stock. The company has a consensus rating of “Hold” and an average target price of $2.67.

Shares of Corindus Vascular Robotics (CVRS) traded up 0.68% during midday trading on Monday, hitting $1.48. 902,994 shares of the stock were exchanged. The company’s market cap is $277.20 million. The firm has a 50-day moving average price of $1.72 and a 200-day moving average price of $1.30. Corindus Vascular Robotics has a 12-month low of $0.40 and a 12-month high of $2.25.

Corindus Vascular Robotics (NYSEMKT:CVRS) last posted its quarterly earnings results on Tuesday, August 8th. The medical equipment provider reported ($0.04) EPS for the quarter, beating the Thomson Reuters’ consensus estimate of ($0.05) by $0.01. Corindus Vascular Robotics had a negative net margin of 1,272.20% and a negative return on equity of 181.63%. The business had revenue of $2.26 million during the quarter, compared to analyst estimates of $3.10 million. On average, equities analysts predict that Corindus Vascular Robotics will post ($0.21) EPS for the current year.

WARNING: This report was first posted by The Cerbat Gem and is the property of of The Cerbat Gem. If you are reading this report on another website, it was stolen and reposted in violation of United States and international copyright & trademark law. The original version of this report can be viewed at https://www.thecerbatgem.com/2017/08/19/corindus-vascular-robotics-inc-cvrs-downgraded-by-bidaskclub-to-hold-updated-updated-updated.html.

Hedge funds have recently modified their holdings of the stock. Goldman Sachs Group Inc. increased its stake in shares of Corindus Vascular Robotics by 147.8% in the second quarter. Goldman Sachs Group Inc. now owns 58,824 shares of the medical equipment provider’s stock valued at $109,000 after buying an additional 35,086 shares in the last quarter. Rhumbline Advisers increased its stake in shares of Corindus Vascular Robotics by 67.6% in the second quarter. Rhumbline Advisers now owns 80,868 shares of the medical equipment provider’s stock valued at $150,000 after buying an additional 32,608 shares in the last quarter. New York State Common Retirement Fund increased its stake in shares of Corindus Vascular Robotics by 334.6% in the second quarter. New York State Common Retirement Fund now owns 89,100 shares of the medical equipment provider’s stock valued at $166,000 after buying an additional 68,599 shares in the last quarter. Bank of New York Mellon Corp increased its stake in shares of Corindus Vascular Robotics by 6.3% in the first quarter. Bank of New York Mellon Corp now owns 163,012 shares of the medical equipment provider’s stock valued at $214,000 after buying an additional 9,684 shares in the last quarter. Finally, California State Teachers Retirement System increased its stake in shares of Corindus Vascular Robotics by 34.4% in the second quarter. California State Teachers Retirement System now owns 148,558 shares of the medical equipment provider’s stock valued at $276,000 after buying an additional 38,000 shares in the last quarter.

About Corindus Vascular Robotics

Corindus Vascular Robotics, Inc is engaged in robotic-assisted vascular interventions. The Company’s CorPath System is a medical device that brings robotic-assisted precision to radial, coronary and peripheral procedures. The workstation allows the physician greater control and the freedom from wearing heavy lead protective equipment that causes musculoskeletal injuries.

Receive News & Stock Ratings for Corindus Vascular Robotics Inc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Corindus Vascular Robotics Inc and related stocks with our FREE daily email newsletter.